Product Expansion Leverage JAMP’s extensive portfolio of nearly 350 generic molecules and biosimilars (BioJAMP, JAMP Acute Care and Injectables) to identify cross-sell opportunities with hospitals, clinics, and wholesalers seeking broad Canadian access to generics and biosimilars.

Domestic Manufacturing With ownership of a 100,000-square-foot Lévis facility and recent Canadian capacity expansion, target national and regional distributors and COGS-sensitive buyers facing drug shortages to position JAMP as a reliable local supplier.

Therapeutic Focus Capitalize on recent launches such as Enzalutamide and biosimilars PEXEGRA and FILRA to pursue hospitals and specialty pharmacies requiring stable access to prostate cancer therapies and biosimilars, aligning sales motions to oncology and immunology channels.

OTC Growth Explore opportunities with Groupe Wampole’s 12 natural health and cosmetic brands to expand OTC product lines through retail chains and online marketplaces, leveraging cross-brand promotions to broaden market reach.

Strategic Partnerships Position JAMP as a strategic partner for provincial healthcare programs and private payers by showcasing integrated capabilities across generics, biosimilars, injectables, and contract manufacturing, addressing supply security and access goals.